Radotinib Y10505 is an anthracycline antibiotic with

is an anthracycline antibiotic with antineoplastic activity

6-diamino-2

InChi: InChI=1S/C53H56F3N7O7S2/c1-32-45(72-31-59-32)36-11-9-33(10-12-36)28-58-47(66)43-26-40(64)29-61(43)48(67)46(51(2

Betamethasone hydrochloride is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activities

but not UCH-L3

Radotinib Y10505 is an anthracycline antibiotic withRadotinib, also known as IY 5511, is an orally available, a second generation tyrosine kinase inhibitor of Bcr Abl fusion protein and the platelet derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR